^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Colon Cancer
    Drug:Zirabev (bevacizumab-bvzr) (VEGF-A inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: A1 - Approval
    Source:
    FDA
    Published date:
    02/09/2021
    Excerpt:
    ZIRABEV is not indicated for adjuvant treatment of colon cancer.